Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12616001517460
Ethics application status
Approved
Date submitted
1/11/2016
Date registered
3/11/2016
Date last updated
9/02/2021
Date data sharing statement initially provided
9/02/2021
Type of registration
Prospectively registered
Titles & IDs
Public title
Early PARacetamol (EPAR) to promote early closure of the ductus arteriosus in preterm infants
Query!
Scientific title
Early PARacetamol (EPAR) to promote early closure of the ductus arteriosus in preterm infants
Query!
Secondary ID [1]
290438
0
None
Query!
Universal Trial Number (UTN)
U1111-1189-3203
Query!
Trial acronym
EPAR study
Query!
Linked study record
N/A
Query!
Health condition
Health condition(s) or problem(s) studied:
Patent ductus arteriosus
300791
0
Query!
Condition category
Condition code
Cardiovascular
300617
300617
0
0
Query!
Other cardiovascular diseases
Query!
Reproductive Health and Childbirth
300634
300634
0
0
Query!
Complications of newborn
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Intravenous paracetamol at a dose of 15 mg/kg (1.5 ml/kg) as a single bolus, followed by 7.5 mg/kg (0.75 ml/kg) every 6 hours for five days
Query!
Intervention code [1]
296283
0
Treatment: Drugs
Query!
Comparator / control treatment
5% dextrose 1.5 ml/kg as a single bolus, followed by 0.75 ml/kg every 6 hours for five days
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
300030
0
Any intervention for management of PDA up to five days
Query!
Assessment method [1]
300030
0
Query!
Timepoint [1]
300030
0
The need for medical or surgical intervention will be assessed by review of the medical record at 5 days of life
Query!
Secondary outcome [1]
328859
0
Closure of ductus arteriosus at five days
Query!
Assessment method [1]
328859
0
Query!
Timepoint [1]
328859
0
Closure of the ductus arteriosus will be assessed by ultrasound scan at 5 days of life
Query!
Secondary outcome [2]
328860
0
Size of ductus arteriosus at 48 hours and five days
Query!
Assessment method [2]
328860
0
Query!
Timepoint [2]
328860
0
The size of the ductus arteriosus will be measured by ultrasound scan in millimetres at 48 hours and 5 days of life
Query!
Secondary outcome [3]
328861
0
Ductal reopening during admission
Query!
Assessment method [3]
328861
0
Query!
Timepoint [3]
328861
0
Ductal reopening will be assessed by review of the medical record for each infant at first discharge home
Query!
Secondary outcome [4]
328862
0
Ductus arteriosus parameters (excluding size and pattern)
Query!
Assessment method [4]
328862
0
Query!
Timepoint [4]
328862
0
This will be assessed using ultrasound at 48 hours and 5 days of life. Diastolic flow in the descending aorta will be assessed and will be categorised into one of retrograde, absent or antegrade. Left pulmonary artery diastolic velocity will be assessed and recorded.
Query!
Secondary outcome [5]
328863
0
Systemic blood flow measurements
Query!
Assessment method [5]
328863
0
Query!
Timepoint [5]
328863
0
Measures of systemic blood flow will be assessed and measured in ml/kg/min at 48 hours and 5 days of life. This will include the left ventricular outflow, right ventricular outflow and superior vena cava blood flow.
Query!
Secondary outcome [6]
328864
0
Mortality
Query!
Assessment method [6]
328864
0
Query!
Timepoint [6]
328864
0
Assessed by review of the discharge status in the medical record
Query!
Secondary outcome [7]
328906
0
Ductus arteriosus flow pattern
Query!
Assessment method [7]
328906
0
Query!
Timepoint [7]
328906
0
The ductus arteriosus flow pattern will be assessed by ultrasound scan at 48 hours and 5 days of life and categorised into one of bidirectional, growing, pulsatile, closing or closed
Query!
Secondary outcome [8]
328908
0
Necrotising enterocolitis
Query!
Assessment method [8]
328908
0
Query!
Timepoint [8]
328908
0
Assessed by review of the medical record for each infant at time of first hospital discharge to home
Query!
Secondary outcome [9]
328909
0
Sepsis
Query!
Assessment method [9]
328909
0
Query!
Timepoint [9]
328909
0
Assessed by review of the medical record for each infant at time of first hospital discharge to home
Query!
Secondary outcome [10]
328910
0
Intraventricular haemorrhage
Query!
Assessment method [10]
328910
0
Query!
Timepoint [10]
328910
0
Assessed by review of the medical record for each infant at time of first hospital discharge to home
Query!
Secondary outcome [11]
328911
0
Periventricular leukomalacia
Query!
Assessment method [11]
328911
0
Query!
Timepoint [11]
328911
0
Assessed by review of the medical record for each infant at time of first hospital discharge to home
Query!
Secondary outcome [12]
328912
0
Chronic lung disease
Query!
Assessment method [12]
328912
0
Query!
Timepoint [12]
328912
0
Assessed by review of the medical record for each infant at time of first hospital discharge to home
Query!
Secondary outcome [13]
328913
0
Retinopathy of prematurity
Query!
Assessment method [13]
328913
0
Query!
Timepoint [13]
328913
0
Assessed by review of the medical record for each infant at time of first hospital discharge to home
Query!
Secondary outcome [14]
332368
0
Neurodevelopment using Bayley Scales of Infant and Toddler Development, Third Edition
(Bayley-III) and Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition
(WPPSI- IV)
Query!
Assessment method [14]
332368
0
Query!
Timepoint [14]
332368
0
2-3 years corrected age (Bayley-III)
5 years of age (WPPSI-IV
Query!
Eligibility
Key inclusion criteria
Preterm infants <6 hours old
Born at <29 weeks gestation
Informed parental consent
Ductus arteriosus characteristics
- Patent >1 mm
- <30% right to left shunt
Query!
Minimum age
No limit
Query!
Query!
Maximum age
6
Hours
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Known congenital anomalies
Haemodynamic instability (>1 ionotropic agent)
Abnormal baseline liver function
- Transaminases >50% above upper reference range
- Bilirubin above local guideline for exchange transfusion
Ductus arteriosus characteristics
- <1 mm
- >30% right to left shunt
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelopes
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using computerised sequence generation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Randomisation will be stratified based on
Gestation <27 weeks
Duct size >1.5 mm
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
All tests of the effect of treatment on outcomes will be conducted on an intention-to-treat basis. That is, all randomized patients will be analysed in the group to which they were randomised regardless of whether they received the assigned treatment and regardless of any protocol deviations or violations. Analyses of outcome variables will, however, exclude data from infants who withdraw from study treatment and withdraw consent for use of their data. All primary statistical analyses will be unadjusted and tests of significance will be two-sided. Any departures from intention-to-treat will be documented and reported. With regard to sample size calculation for our initial studies we propose the following:
Assuming that approximately 60% of infants in this study would otherwise have required intervention for PDA, a sample size of at least 42 infants per group would be required to detect a 50% reduction in the need for intervention, with a 95% confidence interval and a power of 80%.
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Data collected is being analysed
Query!
Reason for early stopping/withdrawal
Other reasons/comments
Query!
Other reasons
Stopping criteria met at interim analysis
Query!
Date of first participant enrolment
Anticipated
14/11/2016
Query!
Actual
12/11/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
23/03/2019
Query!
Date of last data collection
Anticipated
Query!
Actual
3/07/2019
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
58
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Funding & Sponsors
Funding source category [1]
294845
0
Charities/Societies/Foundations
Query!
Name [1]
294845
0
Running for Premature Babies
Query!
Address [1]
294845
0
Royal Hospital for Women Foundation
Barker St
Randwick NSW 2031
Query!
Country [1]
294845
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Timothy Schindler
Query!
Address
Department of Newborn Care
Royal Hospital for Women
Barker St
Randwick NSW 2031
Query!
Country
Australia
Query!
Secondary sponsor category [1]
293683
0
None
Query!
Name [1]
293683
0
Query!
Address [1]
293683
0
Query!
Country [1]
293683
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
296230
0
South Eastern Sydney Local Health District (Northern Sector)
Query!
Ethics committee address [1]
296230
0
Prince of Wales Hospital G71 East Wing Edmund Blacket Building Prince of Wales Hospital Cnr High and Avoca Street Randwick NSW 203`1
Query!
Ethics committee country [1]
296230
0
Australia
Query!
Date submitted for ethics approval [1]
296230
0
26/08/2015
Query!
Approval date [1]
296230
0
24/02/2016
Query!
Ethics approval number [1]
296230
0
15/232 (HREC/15/POWH/448)
Query!
Summary
Brief summary
The optimal management of PDA is highly controversial with a lack of consensus regarding the need to treat, timing of intervention, the most appropriate pharmacological agents (including dose, dose intervals, duration, repeat courses, routes of administration) and the role of surgical intervention. Traditionally, the medications we use to treat PDA are non-steroidal anti-inflammatory drugs (NSAIDs), which decrease prostaglandin production by inhibiting cyclooxygenases (COX). The most commonly used medications, indomethacin and ibuprofen, have a success rate of approximately 70% - 85%. Unfortunately these medications are associated a number of unwanted adverse effects due to decreased blood flow to the brain, gastrointestinal tract and kidneys. Exposure to these medications puts vulnerable preterm infants at risk of significant complications such as intestinal perforation and necrotising enterocolitis. The alternative to medications is surgical intervention, which also carries significant risks, particularly for extreme preterm infants. Paracetamol is a medication with an excellent safety profile in infants when used to treat mild to moderate pain and fever. Although the mechanism of action of paracetamol is not completely understood, part of its spectrum of activity resembles that of a COX-2 selective inhibitor. Similar to traditional NSAIDs, this results in decreased prostaglandin production. It is therefore intuitive that this may also be effective in promoting ductal closure without the adverse effects associated with NSAIDs. Early experiences with the use of paracetamol for ductal closure have been encouraging. Paracetamol appears to have similar efficacy to NSAIDs, without the gastrointestinal complications associated with NSAIDs, and is well tolerated in the preterm infant population. It has been suggested as a safe alternative medication in situations where other medications have failed or are contraindicated. The aims of this study are to study the effect of early treatment of patent ductus arteriosus with paracetamol and to examine the safety and efficacy profile of paracetamol during the early postnatal period. We hypothesise that early treatment with paracetamol will reduce the number of infants requiring intervention for PDA and that the use of paracetamol in preterm infants with a patent ductus arteriosus will result in a higher rate of ductal closure compared with placebo. We also am to show that paracetamol can be used safely in preterm infants during the early postnatal period.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
70090
0
Dr Timothy Schindler
Query!
Address
70090
0
Department of Newborn Care
Royal Hospital for Women
Barker St
Randwick NSW 2031
Query!
Country
70090
0
Australia
Query!
Phone
70090
0
+61293826190
Query!
Fax
70090
0
+61293826191
Query!
Email
70090
0
[email protected]
Query!
Contact person for public queries
Name
70091
0
Timothy Schindler
Query!
Address
70091
0
Department of Newborn Care
Royal Hospital for Women
Barker St
Randwick NSW 2031
Query!
Country
70091
0
Australia
Query!
Phone
70091
0
+61293826190
Query!
Fax
70091
0
+61293826191
Query!
Email
70091
0
[email protected]
Query!
Contact person for scientific queries
Name
70092
0
Timothy Schindler
Query!
Address
70092
0
Department of Newborn Care
Royal Hospital for Women
Barker St
Randwick NSW 2031
Query!
Country
70092
0
Australia
Query!
Phone
70092
0
+61293826190
Query!
Fax
70092
0
+61293826191
Query!
Email
70092
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Risks to individual patient confidentiality
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
10511
Study protocol
Schindler T, Smyth J, Bolisetty S, Michalowski J, Lui K. Early PARacetamol (EPAR) trial: a study protocol for a randomised controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. BMJ Open. 2019 Oct 30;9(10):e031428. doi: 10.1136/bmjopen-2019-031428.
10512
Informed consent form
[email protected]
10513
Ethical approval
[email protected]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Early PARacetamol (EPAR) trial: a study protocol for a randomised controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants.
2019
https://dx.doi.org/10.1136/bmjopen-2019-031428
Embase
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.
2020
https://dx.doi.org/10.1002/14651858.CD013278.pub2
Embase
Early PARacetamol (EPAR) Trial: A Randomized Controlled Trial of Early Paracetamol to Promote Closure of the Ductus Arteriosus in Preterm Infants.
2021
https://dx.doi.org/10.1159/000515415
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF